Biliary Atresia
61
15
17
20
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.9%
3 terminated out of 61 trials
87.0%
+0.5% vs benchmark
8%
5 trials in Phase 3/4
30%
6 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (61)
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
Biliary Atresia Research Network Northeast
Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
Tolerability of Enteral NAC in Infants
The Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis
Kasai Portoenterostomy Timing and Outcomes in Biliary Atresia
Nutritional Intervention for Biliary Atresia
Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy
Biliary Atresia Study in Infants and Children
A Prospective Database of Infants With Cholestasis
Mapping Disease Pathways for Biliary Atresia
Stool Card in Biliary Atresia
Intestinal Microbiome Composition in Infants With Biliary Atresia (BA)
Clinical Outcomes of Early Kasai Surgery With Umbilical Cord MSCs in Biliary Atresia
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia
Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
Stem Cell Applications in Biliary Atresia Patients